Table 3 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors

Rémi Vernet; Eugenio Fernández; Denis Migliorini; Virginie Ancrenaz; Emily Charrier; Marie‐Claude Belkouch; Olivier Von Rohr; Muriel Urwyler; Claudio De Vito; Jessica Renaux; Jean Villard; Olivier Rubin; Julien Grogg; Nicolas Mach

doi:10.1158/2767-9764.26644208.v1

August 14, 2024Open Access

Table 3 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors

View Full Paper

Ask AI

Bookmark

Share

Key Points

Tumor responses were characterized according to RECIST criteria after MVX-ONCO-1 treatment, documenting clinical disease control across advanced solid tumors.
First-in-human phase I clinical study evaluated personalized active immunotherapy protocols, assessing safety profiles and therapeutic activity in solid tumors.
Evidence highlights feasibility for active immunotherapy platforms targeting solid tumors, but additional clinical trials are necessary to confirm clinical benefit.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Phase I study reports tumor responses according to RECIST in advanced solid tumors, indicating preliminary activity of personalized active immunotherapy.

Abstract

Tumor responses according to RECIST

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Vernet et al. (2024) studied this question.

synapsesocial.com/papers/68e5c62db6db64358755d2e9 https://doi.org/10.1158/2767-9764.26644208.v1

View Full Paper

Ask AI

Bookmark

Share

Table 3 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Table 3 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading